or Try an Advanced Search...

    Technical Analysis for EWTX - Edgewise Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 17.05 5.44% 0.88
    EWTX closed up 5.44 percent on Monday, April 29, 2024, on 85 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: May 9
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical EWTX trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    20 DMA Resistance Bearish 5.44%
    50 DMA Resistance Bearish 5.44%
    Shooting Star Candlestick Bearish 5.44%
    Gapped Down Weakness 6.96%
    NR7 Range Contraction 5.83%
    Oversold Stochastic Weakness 5.83%
    Stochastic Buy Signal Bullish 8.95%
    Older End-of-Day Signals for EWTX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 22 hours ago
    Up 1 ATR about 22 hours ago
    Rose Above 50 DMA about 22 hours ago
    Rose Above Previous Day's High about 22 hours ago
    50 DMA Resistance about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    EWTX Chart by TradingView
    Basic chart:

    Profile

    Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Muscular Dystrophy Small Molecule Therapies Limb Girdle Muscular Dystrophies Muscle Disorders

    Is EWTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 23 Edgewise gets EU orphan drug status for muscular dystrophy drug
    Apr 23 Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
    Apr 15 Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
    Mar 28 Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
    Mar 27 Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
    Mar 5 Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
    Feb 28 Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
    Feb 26 Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
    Feb 22 Edgewise Therapeutics Non-GAAP EPS of $0.47
    Feb 22 Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    See more EWTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.6899
    52 Week Low 5.12
    Average Volume 716,959
    200-Day Moving Average 10.63
    50-Day Moving Average 16.77
    20-Day Moving Average 16.35
    10-Day Moving Average 15.90
    Average True Range 1.03
    RSI (14) 55.75
    ADX 12.14
    +DI 24.14
    -DI 17.11
    Chandelier Exit (Long, 3 ATRs) 16.12
    Chandelier Exit (Short, 3 ATRs) 17.99
    Upper Bollinger Bands 17.95
    Lower Bollinger Band 14.75
    Percent B (%b) 0.72
    BandWidth 19.55
    MACD Line -0.20
    MACD Signal Line -0.27
    MACD Histogram 0.0719
    Fundamentals Value
    Market Cap 1.57 Billion
    Num Shares 92.3 Million
    EPS -1.40
    Price-to-Earnings (P/E) Ratio -12.18
    Price-to-Sales 0.00
    Price-to-Book 6.29
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 19.06
    Resistance 3 (R3) 19.02 18.32 18.73
    Resistance 2 (R2) 18.32 17.80 18.34 18.61
    Resistance 1 (R1) 17.68 17.49 18.00 17.72 18.50
    Pivot Point 16.98 16.98 17.14 17.00 16.98
    Support 1 (S1) 16.34 16.46 16.66 16.38 15.60
    Support 2 (S2) 15.64 16.15 15.66 15.49
    Support 3 (S3) 15.00 15.64 15.38
    Support 4 (S4) 15.04